RxDoctor Payments Data

Naveed Ansari, MD

Ophthalmology · Arlington Heights, ILNPI 1922101559

Payments from drug & device makers

$7,011in general payments, 2019–2025

Across 185 payments — averaging $37.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Alcon$850
  • Bausch & Lomb Americas Inc.$766
  • Rxsight Inc$664
  • Biotissue Holdings Inc.$484
  • Johnson & Johnson Surgical Vision, Inc.$437
  • plus $3K from 21 others

What the payments were for

  • Food & beverage$6,993100%
  • Education$180%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,011 in reported general payments places this provider in the 80th percentile of 773 ophthalmology providers in Illinois.

See all ophthalmology providers in Illinois

Medicare billing

Part B allowed, 2024
$398,763
Medicare patients
1,241
Services billed
2,864

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine72$91,279
XiidraLifitegrast32$37,403
LumiganBimatoprost45$24,735
Cyclosporine19$8,479
ProlensaBromfenac Sodium16$5,572
Latanoprost449$5,484
Prednisolone Acetate123$4,708
Travoprost24$4,198
Fluorometholone28$2,508
TafluprostTafluprost/Pf16$2,085
Timolol Maleate111$1,887
ValacyclovirValacyclovir Hcl39$1,689
ErythromycinErythromycin Base103$980
Brimonidine Tartrate26$860
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat60$776

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan$1,112$116,014117 claims
Bausch & Lomb Americas Inc.Xiidra$766$37,40332 claims
Bausch & Lomb, A Division Of Bausch Health US, LLCProlensa$15$5,57216 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 773 ophthalmology providers in Illinois.

Other ophthalmology in Arlington Heights

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →